Home › Neuroendocrine Carcinoma › Texas
Neuroendocrine Carcinoma clinical trials in Texas
8 studies for Neuroendocrine Carcinoma are looking for participants at sites in Texas.
Cities in Texas
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
- NEXT Dallas, Dallas
- START Dallas- Fort Worth, Dallas
- MD Anderson Cancer Center, Houston
- and 2 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT07080242A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
- UT Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT07488923A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Texas Oncology - West Texas, Amarillo
- Texas Oncology, P.A., Dallas
- Texas Oncology Gulf Coast, Pearland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT06330064A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
- Crinetics Study Site, Austin
- Crinetics Study Site, Houston
- Crinetics Study Site, Irving
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT07129252A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- Mays Cancer Center / University of Texas, San Antonio, San Antonio
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 15, 2026 · NCT05652686A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
- The University of Texas MD Anderson Cancer Center, Houston
- Oncology Consultants, PA- Houston, Houston
- Next Oncology Dallas, Irving
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 9, 2026 · NCT07174583A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- UT Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated May 27, 2026 · NCT03093116A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Dec 11, 2025 · NCT06943521From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.